Brief: Virios Therapeutics Says Plans To Advance Lead Candidate IMC-1 To Phase 3 Development For Treatment Of Fibromyalgia
09/08/2023 12:08
Aug 9 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS ANNOUNCES PLANS TO ADVANCE LEAD
CANDIDATE
IMC-1 TO PHASE 3 DEVELOPMENT AS A NEW TREATMENT OPTION FOR
FIBROMYALGIA
* VIRIOS THERAPEUTICS INC - TO BEGIN ENROLLMENT IN FIRST
FIBROMYALGIA PHASE 3 SAFETY AND EFFICACY STUDY IN MID-2024
Source text for Eikon: ID:nGNX6pszgj
Further company coverage: VIRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study